Delayed Graft Function clinical trials at UCLA
1 in progress, 0 open to eligible people
Showing trials for
Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Sorry, not currently recruiting here
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Los Angeles, California and other locations
Our lead scientists for Delayed Graft Function research studies include Suphamai Bunnapradist, MD, MS.
Last updated: